Drugs / BT595
BT595
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02859909 | Nov 2016 → Dec 2018 | autoimmune thrombocytopenia | Biotest | Completed | No outcome recorded |
| Phase 3 | NCT02810444 | Oct 2016 → Apr 2020 | immunodeficiency disease | Biotest | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-07 | Biotest | US Food and Drug Administration FDA akzeptiert den Zulassungsantrag für Immunglobulin Yimmugo biotest.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT595 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02810444 ↗ |
| Known as | IVIg | “This trial investigated the efficacy and safety of the new 10% human intravenous immunoglobulin (IVIg) BT595 (Yimmugo®).” PMID 36448274 ↗ Nov 2022 |
| Known as | Yimmugo | “This trial investigated the efficacy and safety of the new 10% human intravenous immunoglobulin (IVIg) BT595 (Yimmugo®).” PMID 36448274 ↗ Nov 20221“a new, highly purified 10% IVIg (BT595, Yimmugo®)” PMID 35944615 ↗ Aug 2022 |
| Modality | Protein / enzyme biologic | “10% human intravenous immunoglobulin” PMID 36448274 ↗ Nov 2022 |
| Route | Intravenous | “for Intravenous Administration BT595” NCT02810444 ↗ |